Targets › BLEOMYCIN
1 program from 1 company in 2 trials: 2 Phase 3; Oncology.
Open in Phaseline: the race on BLEOMYCIN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | bleomycin sulfate DNA/RNA crosslinking and degradation | BLEOMYCIN | Phase 3 | Lymphoma | – |
Lymphoma (2)
mixed (1)
European Organisation for Research and Treatment of Cancer - EORTC (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.